BOSTON ( TheStreet) -- It's time to introduce the Biotech Stock Mailbag Readers' Portfolio.My request for your favorite 2010 biotech stock picks brought in nominations for 93 different stocks. I'm really pleased with the response, so thanks to everyone who participated. I decided to narrow down the list of nominees to a manageable portfolio of 20 stocks. These reader-suggested stocks will form the basis of the Biotech Stock Mailbag Readers' Portfolio (BSMRP), which I'll update and write about regularly throughout the year. Let's take a closer look at the stocks that make up the BSMRP. Of the 93 stocks submitted, ten received three or more votes, so they were immediately seated into the portfolio. ImmunoGen ( IMGN) received the most recommendations, with seven votes total. Curis ( CRIS), Allos Therapeutics ( ALTH) and Ariad Pharmaceuticals ( ARIA) each received four votes. Six stocks received three votes each: GenVec ( GNVC), Vertex Pharmaceuticals ( VRTX), Vivus ( VVUS), StemCells ( STEM), Spectrum Pharmaceuticals ( SPPI) and Mannkind ( MNKD). My job became a bit trickier when deciding how to fill the remaining ten portfolio slots, which needed to come from the 20 stocks that received two votes apiece from readers.
I picked China Medical Technologies ( CMED) because the BSMRP should have some international flavor. Cell Therapeutics ( CTIC) and Geron ( GERN) both make it simply because they seem to be lightning rods for controversy, which will make the portfolio that much more interesting to follow. Watching another stem-cell stock -- in the form of Geron -- also seemed like a good idea. With two portfolio slots remaining and 12 stocks available, I wrote each down on a slip of paper and threw them into my winter hat. The luck of the draw resulted in the addition of Seattle Genetics ( SGEN) and Celldex Therapeutics ( CLDX).
- Just over half the stocks in the portfolio have a cancer focus. That's probably a bit overweight but not a surprise given investors' love affair with cancer drug stocks.
- Despite the heavy cancer tilt, the BSMRP is reasonably diversified across different disease categories, with hepatitis C (Vertex), stem cells (Geron, StemCells) diabetes (Mannkind), obesity (Vivus) and lupus (Human Genome) all represented.
- All the stock selections are long picks. I only received two short recommendations -- Cell Therapeutics and Vertex.
- Readers don't seem to be very much interested in the large-cap biotech class. Gilead Sciences (GILD), Amgen (AMGN) and Celgene (CELG) received a single nomination apiece.